Kyntra Bio says FibroGen Europe unit settles bankruptcy obligations for about $0.1 million
KYNB•FibroGen Europe unit settles bankruptcy obligations
- Kyntra Bio’s FibroGen Europe unit settled bankruptcy-related product development obligations and accrued interest for about USD 0.1 million.
- The liabilities totaled USD 19.2 million at filing, driving a non-operating gain in Q2 2026.
